Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084461 · ClinicalTrials.gov registry record · Phase 2
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00084461: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00084461 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084461, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- OTHER laboratory biomarker analysis
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084461
The ClinicalTrials.gov registry entry for NCT00084461 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00084461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084461 about?
NCT00084461 is a clinical study titled "Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors". Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00084461?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00084461?
The interventions under investigation include: laboratory biomarker analysis (OTHER), romidepsin (DRUG).
Who is sponsoring clinical trial NCT00084461?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.